Medical devices, healthcare technology and the business of care
510(k) clearance · K263120

Xpert Xpress CoV-2/Flu plus

Cepheid · Decision date Oct 2, 2026

MEDTECHLEDGER EXPLANATIONK263120

What did the FDA decide?

Cepheid received a substantially equivalent determination for the Xpert Xpress CoV-2/Flu plus under 510(k) K263120, with a decision date of 10/02/2026 and a receipt date of 09/04/2026. The device falls under product code QOF (Class II, 21 CFR 866.3981, Microbiology panel), with subsequent product code OOI (21 CFR 862.2570, Clinical Chemistry panel). The FDA decision summary describes the submission as covering modifications to Cepheid's own previously cleared Class II device.

The recorded change was a software modification to mask an analyte; the summary states that no new performance data were reviewed and that the indications for use and fundamental scientific technology were unchanged. CLIA records list the Xpert Xpress CoV-2/Flu plus on the GeneXpert Dx and GeneXpert Infinity systems for Influenza A/B and SARS-CoV-2 at moderate complexity, effective 10/09/2026. The specific analyte masked, the predicate device's 510(k) number, and any performance characteristics are not stated in the available excerpts.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Oct 2, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K263120
Regulatory pathway
510(k) premarket notification
Applicant
Cepheid
Product code
QOF
Decision code
SESE
Decision date
Oct 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents.

Applicant
Cepheid
Product code
QOF
FDA device class
2

FDA decision timeline

  1. K263120 received

    Application receipt date recorded by FDA.

  2. K263120 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QOF

Product / regulatory recordCompanyPathwayDecision dateSource
GenMark Diagnostics, Inc.510(k) clearanceOct 30, 2026FDA
Cepheid510(k) clearanceOct 22, 2026FDA
Cepheid510(k) clearanceSep 25, 2026FDA
Biofire Diagnostics510(k) clearanceSep 22, 2026FDA
Baebies, Inc.510(k) clearanceSep 11, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cepheid

Headquarters
Not reported
Brand website
cepheid.com
FDA applicant address
Sunnyvale, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records